Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
R Bi, L Chen, M Huang, Z Qiao, Z Li, G Fan… - Biochimica et Biophysica …, 2024 - Elsevier
The utilization of PARP inhibitors (PARPis) has significantly improved the prognosis for
ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi …
ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi …
A Predictive Model for Initial Platinum‐Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue‐Derived Small …
S Shen, C Wang, J Gu, F Song, X Wu… - Journal of …, 2024 - Wiley Online Library
Epithelial ovarian cancer (EOC) is an often‐fatal malignancy marked by the development of
resistance to platinum‐based chemotherapy. Thus, accurate prediction of platinum drug …
resistance to platinum‐based chemotherapy. Thus, accurate prediction of platinum drug …
Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort
Purpose: Homologous recombination deficiency (HRD) impacts cancer treatment strategies,
particularly the effectiveness of PARP inhibitors. However, the variability different HRD …
particularly the effectiveness of PARP inhibitors. However, the variability different HRD …
Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection
L Schejbel, TS Poulsen, LK Vestergaard… - Molecular Diagnosis & …, 2024 - Springer
Introduction Testing for homologous recombination deficiency (HRD) as a biomarker in
relation to poly (ADP-ribose) polymerase inhibitor (PARPi) treatment in ovarian cancer is …
relation to poly (ADP-ribose) polymerase inhibitor (PARPi) treatment in ovarian cancer is …
[HTML][HTML] Comprehensive evaluation of genomic and functional assays for homologous recombination deficiency with high-grade epithelial ovarian cancer: Platinum …
Z Feng, C Zhu, X Zhang, Z Huang, X Ju, Q Guo… - International Journal of …, 2024 - Elsevier
Objective Homologous recombination deficiency assays, guiding treatment of Poly (ADP-
ribose) polymerase inhibitors, are increasingly applied in clinics. This study aimed to …
ribose) polymerase inhibitors, are increasingly applied in clinics. This study aimed to …
Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer
TPH Nguyen, NHB Tran, TA Nguyen, MTT Ngo… - medRxiv, 2024 - medrxiv.org
Backgrounds: Assessing homologous recombination deficiency (HRD) has been
recommended by clinical guidelines for patients with ovarian cancer (OC) as it predicts …
recommended by clinical guidelines for patients with ovarian cancer (OC) as it predicts …
Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural Variants
Purpose Homologous recombination deficiency (HRD) impacts cancer treatment strategies,
particularly effective utilization of PARP inhibitors. However, the variability of different HRD …
particularly effective utilization of PARP inhibitors. However, the variability of different HRD …